Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective
Jan Damoiseaux,Luis Eduardo Coelho Andrade,Orlando Gabriel Carballo,Karsten Conrad,Paulo Luiz Carvalho Francescantonio,Marvin J. Fritzler,Ignacio García-De La Torre,Manfred Herold,Werner Klotz,Wilson de Melo Cruvinel,Tsuneyo Mimori,Carlos Alberto von Mühlen,Minoru Satoh,Edward K. L. Chan +13 more
Reads0
Chats0
TLDR
The ICAP consensus is presented on the clinical relevance of the 29 distinct HEp-2 IIFA patterns: this clinical relevance is primarily defined within the context of the suspected disease and includes recommendations for follow-up testing.Abstract:
The indirect immunofluorescence assay (IIFA) on HEp-2 cells is widely used for detection of antinuclear antibodies (ANA). The dichotomous outcome, negative or positive, is integrated in diagnostic and classification criteria for several systemic autoimmune diseases. However, the HEp-2 IIFA test has much more to offer: besides the titre or fluorescence intensity, it also provides fluorescence pattern(s). The latter include the nucleus and the cytoplasm of interphase cells as well as patterns associated with mitotic cells. The International Consensus on ANA Patterns (ICAP) initiative has previously reached consensus on the nomenclature and definitions of HEp-2 IIFA patterns. In the current paper, the ICAP consensus is presented on the clinical relevance of the 29 distinct HEp-2 IIFA patterns. This clinical relevance is primarily defined within the context of the suspected disease and includes recommendations for follow-up testing. The discussion includes how this information may benefit the clinicians in daily practice and how the knowledge can be used to further improve diagnostic and classification criteria.read more
Citations
More filters
Journal ArticleDOI
Increasing Prevalence of Antinuclear Antibodies in the United States.
Gregg E. Dinse,Christine G. Parks,Clarice R. Weinberg,Caroll A. Co,Jesse Wilkerson,Darryl C. Zeldin,Edward K. L. Chan,Frederick W. Miller +7 more
TL;DR: This study was undertaken to investigate whether the prevalence of antinuclear antibodies (ANA), the most common biomarker of autoimmunity, changed over a recent 25‐year span in the US.
Journal ArticleDOI
239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018.
Journal ArticleDOI
New insights into the role of antinuclear antibodies in systemic lupus erythematosus
TL;DR: The authors re-examine the role of ANAs in SLE and discuss changing attitudes towards using ANAs as biomarkers, suggesting that more regular serological testing could illuminate changes relevant to pathogenesis and disease status.
Journal ArticleDOI
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases.
TL;DR: Clinicians should be aware of the type of assay used for antinuclear antibody detection and the advantages and disadvantages of using immunofluorescence (IIF) assays and solid phase immunoassays (SPAs) for screening, as well as the clinical relevance of the differences between the techniques.
Journal ArticleDOI
ANA as an entry criterion for the classification of SLE.
TL;DR: These findings suggest caution in positioning ANA positivity as an entry criterion for classification and point to the value of alternative serological approaches for ANA determinations.
References
More filters
Journal ArticleDOI
Systemic lupus erythematosus
Jessica J Manson,Anisur Rahman +1 more
TL;DR: Systemic lupus erythematosus is a relapsing and remitting disease, and treatment aims are threefold: managing acute periods of potentially life-threatening ill health, minimizing the risk of flares during periods of relative stability, and controlling the less life- threatening, but often incapacitating day to day symptoms.
Journal ArticleDOI
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more
TL;DR: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.
Book
Systemic Lupus Erythematosus
TL;DR: Contributions are gathered from physicians and researchers from North America, South America, Europe, and Asia that highlight several important and/or novel aspects of the molecular pathogenesis, clinical organ involvement, and experimental therapies in this prototypical systemic autoimmune disease.
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Peter A. Merkel,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
TL;DR: The detection of antibody to ENA with a well defined specificity allows recognition of an apparently distinct mixed connective tissue disease syndrome which is characterized by an excellent response to corticosteroid therapy and a favorable prognosis.
Related Papers (5)
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
Nancy Agmon-Levin,Nancy Agmon-Levin,Jan Damoiseaux,Cornelis Kallenberg,Ulrich Sack,Torsten Witte,Manfred Herold,Manfred Herold,Xavier Bossuyt,L. Musset,Ricard Cervera,Aresio Plaza-Lopez,Carlos Tadeu dos Santos Dias,Maria José Rego Sousa,Antonella Radice,Catharina Eriksson,Olof Hultgren,Markku Viander,Munther A. Khamashta,Stephan Regenass,Luis Eduardo Coelho Andrade,Allan Wiik,Angela Tincani,Johan Rönnelid,Daniel Bloch,Marvin J. Fritzler,Edward K. L. Chan,I. Garcia-De La Torre,Konstantin N. Konstantinov,Robert Lahita,Merlin R. Wilson,Olli Vainio,Nicole Fabien,Renato Alberto Sinico,Pier Luigi Meroni,Yehuda Shoenfeld,Yehuda Shoenfeld +36 more
Range of antinuclear antibodies in "healthy" individuals
Eng M. Tan,T. E. W. Feltkamp,Josef S. Smolen,Brian T. Butcher,Roger L. Dawkins,Marvin J. Fritzler,Tom P. Gordon,John A. Hardin,Joachim R. Kalden,Robert G. Lahita,Ravinder N. Maini,J. S. McDougal,Naomi F. Rothfield,Ruud J.T. Smeenk,Yoshinari Takasaki,Allan Wiik,Merlin R. Wilson,James A. Koziol +17 more